The Role of Ribose in Patients Diagnosed With Fibromyalgia

Bioenergy Life Science

Status: Suspended

Conditions: Fibromyalgia

Treatments: Dietary Supplement: D-ribose; Other: dextrose

Study type: Interventional

Funder types: Industry

Identifiers

NCT00566514

200604-7

Details and patient eligibility

About

The purose of this research study is to determine the potential benefit of D-ribose, a nutritional supplement (a sugar), versus a placebo (another sugar) in people with fibromyalgia.

Full description

Two hundred to three hundred subjects (equally distribued between placebo and D-ribose) between 18-78 years of age will comprise this study. The final numbers enrolled will depend upon obtaining approximately 100 subjects that can display a high degree of compliance to TID dosing with approximately equal balance between the active and placebo arms.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 78 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• previous diagnosis of fibromomyalgia by a MD
• Has been diagnosed with fibromyalgia and are over 18 years of age
• Does live in the United States

Exclusion criteria

• does NOT have severe medication/chemical/supplement sensitivities
• does NOT have insulin dependent diabetes or other severe illnesses (cancer, hepatitis, congestive heart failure)
• does NOT have rheumatoid arthritis or gout
• previous use of ribose

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

200 participants in 2 patient groups, including a placebo group

1

Active Comparator group

Description:

D-ribose 5 grams TID orally

Treatment:

Dietary Supplement: D-ribose

2

Placebo Comparator group

Description:

Dextrose 5 grams TID

Treatment:

Other: dextrose